[go: up one dir, main page]

WO2023112973A1 - Améliorant de la dyslipidémie contenant de la proanthocyanidine, et aliments fonctionnels, quasi-médicaments et médicaments contenant un améliorant de la dyslipidémie contenant de la proanthocyanidine - Google Patents

Améliorant de la dyslipidémie contenant de la proanthocyanidine, et aliments fonctionnels, quasi-médicaments et médicaments contenant un améliorant de la dyslipidémie contenant de la proanthocyanidine Download PDF

Info

Publication number
WO2023112973A1
WO2023112973A1 PCT/JP2022/046115 JP2022046115W WO2023112973A1 WO 2023112973 A1 WO2023112973 A1 WO 2023112973A1 JP 2022046115 W JP2022046115 W JP 2022046115W WO 2023112973 A1 WO2023112973 A1 WO 2023112973A1
Authority
WO
WIPO (PCT)
Prior art keywords
dyslipidemia
proanthocyanidins
improving
improving agent
proanthocyanidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/046115
Other languages
English (en)
Japanese (ja)
Inventor
梓 鈴木
巌 堤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seed Medical Pharmaceutical Co Ltd
Original Assignee
Seed Medical Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seed Medical Pharmaceutical Co Ltd filed Critical Seed Medical Pharmaceutical Co Ltd
Priority to JP2023553145A priority Critical patent/JP7537812B2/ja
Publication of WO2023112973A1 publication Critical patent/WO2023112973A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to dyslipidemia-improving agents containing proanthocyanidins, and functional foods, quasi-drugs, and pharmaceuticals containing the dyslipidemia-improving agents.
  • proanthocyanidins have been used as food ingredients to improve the condition in which the levels of cholesterol and triglycerides dissolved in the blood are abnormally higher than the standard values (hereinafter referred to as dyslipidemia).
  • Proanthocyanidins are a type of polyphenols consisting of a structure in which multiple flavan-3-ols are linked, and are contained in leaves, fruits, barks, etc. of various plants. While proanthocyanidins are avoided as an astringent component, they are used in foods and quasi-drugs as they are effective for dyslipidemia because they have functions as lipase inhibitors and antioxidants. (For example, Patent Document 1.).
  • Proanthocyanidins have the advantage of being able to exhibit lipase inhibition and antioxidant effects within a short period of time once they are absorbed into the body.
  • the formulated proanthocyanidins are sometimes already oxidized before ingestion, and in this case, the above-mentioned effects are lost, and the storage is poor. Evil was considered a problem.
  • the present invention has been made in view of such circumstances, and can express an effect equivalent to the dyslipidemia improvement effect obtained by taking a predetermined number of times of proanthocyanidins with a smaller number of times of taking, and has storage stability and To provide a dyslipidemia-ameliorating agent with improved usability by improving astringency when ingested.
  • the present invention also provides functional foods, quasi-drugs, and pharmaceuticals containing the same dyslipidemia-improving agent.
  • the dyslipidemia-improving agent according to the present invention is (1) a dyslipidemia-improving agent composed of proanthocyanidin and an agent for improving the feeling of use, wherein the agent for improving the feeling of use is , free catechin and cyclic oligosaccharide.
  • the dyslipidemia improving agent according to the present invention also has the following characteristics.
  • the proanthocyanidin is a mixture of proanthocyanidins derived from at least two plant materials selected from acacia bark, cinnamon and hemp seed.
  • the proanthocyanidin contains a polymer structure of 2 to 8 flavan-3-ols and has a molecular weight of 500 to 2,500.
  • the dosage form is powder, fine granules, granules, hard capsules or tablets.
  • the functional food according to the present invention contains (5) the above-mentioned dyslipidemia improving agent.
  • the quasi-drug according to the present invention contains (6) the above-mentioned dyslipidemia improving agent.
  • the drug according to the present invention contains (7) the above-mentioned dyslipidemia improving agent.
  • the dyslipidemia-improving agent is composed of proanthocyanidins and an agent for improving the feeling of use, and the agent for improving the feeling of use contains a free catechin and a cyclic oligosaccharide. Therefore, a dyslipidemia-improving agent capable of exhibiting an effect equivalent to the dyslipidemia-improving action obtained by taking proanthocyanidins a predetermined number of times with a smaller number of times of ingestion and having improved storage stability and usability is provided. can do.
  • proanthocyanidins are a mixture of proanthocyanidins derived from at least two plant materials selected from acacia bark, cinnamon, and hemp seeds, the dyslipidemia-improving action derived from proanthocyanidins is more consistent. can enjoy.
  • the proanthocyanidin contains a polymer structure of 2 to 8 flavan-3-ols and has a molecular weight of 500 to 2500, the proanthocyanidin-derived dyslipidemia improving effect is more consistent. can enjoy.
  • the dosage form is powder, fine granules, granules, hard capsules or tablets
  • the dosage form suitable for the age group of the ingestor such as young people to the elderly, and the usage environment of the ingestor, such as whether or not it is portable. Ingestion of the dyslipidemia improving agent can be performed.
  • the functional food according to the present invention contains the above-mentioned dyslipidemia-improving agent, it is possible to provide a dyslipidemia-improving agent that can be handled as a functional food.
  • the quasi-drug according to the present invention contains the above-mentioned dyslipidemia-improving agent, it is possible to provide a dyslipidemia-improving agent that can be handled as a quasi-drug.
  • the pharmaceutical according to the present invention contains the above-mentioned dyslipidemia-improving agent, it is possible to provide a dyslipidemia-improving agent that can be handled as a pharmaceutical.
  • FIG. 3 is an explanatory diagram showing test results regarding the presence or absence of constituent components of a feel-enhancing agent.
  • FIG. 2 is an explanatory diagram showing the results of a test in which differences in the origin of proanthocyanidins were investigated.
  • FIG. 4 is an explanatory diagram showing the test results of free catechin, which is a feel-enhancing agent.
  • FIG. 4 is an explanatory diagram showing test results regarding differences in tea leaves as free catechin sources.
  • the present invention relates to a dyslipidemia-improving agent, and in particular, a dyslipidemia-improving agent composed of proanthocyanidins and an agent for improving the feeling of use, wherein the agent for improving the feeling of use contains free catechin and a cyclic oligosaccharide. It relates to a dyslipidemia improving agent characterized by:
  • proanthocyanidins have functions as lipase inhibitors and antioxidants, so they have been added to foods and quasi-drugs for the purpose of improving and preventing dyslipidemia.
  • proanthocyanidins react with digestive enzymes during the process of being absorbed into the body, or lose their action within a short period of time as they are metabolized.
  • one of the reasons is that even if it is formulated, its action is impaired by oxidation before it is ingested.
  • the present inventors have found that, when used in combination with a given composition, the lipase inhibitory action and antioxidant action of proanthocyanidins ingested into the body are expressed for a longer time than when used alone, and dyslipidemia is more easily treated. I thought it could be improved.
  • the present invention has been completed based on such ideas and findings from long-term biochemical research, and is a dyslipidemia improving agent composed of proanthocyanidins, a feeling-improving agent, and the feeling of use.
  • the improver is characterized by blending free catechin and cyclic oligosaccharide.
  • the dyslipidemia-improving action means that LDL cholesterol in the blood is 140 mg/dL or more, HDL cholesterol is less than 40 mg/dL, or triglycerides in the fasting state (for example, no food for 10 hours or more). It refers to a drug that prevents or improves the condition in which is 150 mg/dL or more.
  • dyslipidemia it is possible, for example, to remove plaque formed on the inner wall of blood vessels and prevent plaque formation. Since plaque clogs blood vessels and causes myocardial infarction and cerebral infarction, improving dyslipidemia can prevent these developments.
  • Proanthocyanidins which have an action to improve dyslipidemia, form a carbon bond between the C-4 position of the flavan skeleton of flavan-3-ols and the C-8 position of the flavan skeleton of other flavan-3-ols. It is a compound whose basic skeleton is a structure in which a plurality of Proanthocyanidins are a kind of polyphenols and are contained in leaves, fruits, barks, etc. of various plants.
  • Flavan-3-ols are a group of flavonoids having a 2-phenyl-3,4-dihydro-2H-chromen-3-ol skeleton, such as ( ⁇ )-catechin and (-)-epicatechin.
  • Proanthocyanidins exist in various structures in plants due to modifications such as galloyl groups and sugars.
  • the structure of the proanthocyanidin according to the present embodiment is not particularly limited, it preferably contains a polymer structure of 2 to 8 flavan-3-ols and has a molecular weight of 500 to 2,500. If the molecular weight is less than 500, the dyslipidemia-improving action derived from proanthocyanidins cannot be fully enjoyed.
  • proanthocyanidins are not particularly limited, but proanthocyanidins derived from plant materials such as acacia bark, cinnamon, and hemp seeds have a polymeric structure of 2 to 8 flavan-3-ols. , and a large amount of proanthocyanidins having a molecular weight of 500 to 2,500.
  • proanthocyanidins obtained from any two types of plant materials out of acacia bark, cinnamon, and hemp seeds are higher than when using proanthocyanidins obtained from one type of plant material. It has been found that a stronger dyslipidemia-improving effect is exhibited when used in combination with proanthocyanidins. Furthermore, it has been found that when proanthocyanidins obtained from three kinds of proanthocyanidins are mixed and used, a stronger dyslipidemia ameliorating effect is exhibited than when two kinds of proanthocyanidins are used.
  • the usability improver is an agent for improving the usability felt when proanthocyanidins are ingested.
  • a decrease in the feeling of use due to the cumbersome handling required to prevent it (hereinafter referred to as "handling difficulty"), and the need to take multiple doses per day in conventional proanthocyanidin formulations
  • Handling difficulty Decreased feeling of use due to complexity (hereinafter referred to as “non-sustainability of improvement effect”), decrease of feeling of use due to difficulty in swallowing due to astringency of proanthocyanidins when taken orally (hereinafter referred to as "oral irritation
  • oral irritation is an agent for improving and improving various factors that reduce the feeling of use.
  • the usability improver consists of at least free catechin and cyclic oligosaccharide.
  • Free catechins are unpolymerized monomeric catechins, and are collectively referred to as (-)-catechin, (-)-epicatechin, (-)-gallocatechin, and (-)-epigallocatechin. In particular, it is preferable to contain either (-)-epicatechin or (-)-epigallocatechin as the free catechin.
  • (-)-Epicatechin and (-)-Epigallocatechin have a bitter taste, but the aftertaste is slightly sweet. If these are added to the feeling-improving agent, it becomes possible to reduce the astringent taste of proanthocyanidins and suppress the astringent taste when taken orally.
  • the free catechin is preferably a mixture of free catechins obtained from at least two types of tea leaves selected from green tea leaves, roasted tea leaves, and black tea leaves.
  • any two kinds of tea leaves It has been clarified that a higher dyslipidemia ameliorating effect is exhibited when the obtained free catechins are mixed and used. It has also been clarified that when free catechins obtained from three kinds of tea leaves are mixed and used, they show substantially the same dyslipidemia improvement effect as the two kinds.
  • Cyclic oligosaccharide is a general term for oligosaccharides having a cyclic structure, and is a polysaccharide in which a plurality of glucoses are linked in a ring. More specifically, ⁇ -cyclodextrin consisting of six glucoses, ⁇ -cyclodextrin consisting of 7 glucoses, ⁇ -cyclodextrin consisting of 8 glucoses, and the like. Any of the above cyclodextrins may be employed as the cyclic oligosaccharide according to the present embodiment.
  • Cyclic oligosaccharides have a structure in which the inside of the cyclic structure is hydrophobic and the outside is hydrophilic. Due to such a structure, cyclic oligosaccharides incorporate poorly water-soluble molecules within the cyclic structure and exhibit water solubility due to the hydrophilic action on the outside.
  • the above-mentioned free catechins and cyclic oligosaccharides can improve the storage stability of proanthocyanidins and reduce astringency when used alone, but when used together, these effects can be further enhanced.
  • the dosage form of the dyslipidemia improving agent according to the present embodiment is not particularly limited, and any dosage form such as powder, fine granules, granules, soft capsules, hard capsules, jelly-like, gummy-like, liquid or tablet can be selected. can do.
  • powders, fine granules, granules, hard capsules, or tablets can prevent the interior of the dyslipidemia improving agent from coming into contact with air, thereby preventing deterioration due to oxidation and further increasing storage stability.
  • dyslipidemia improving agent according to the present embodiment can also contain excipients, additives, auxiliary ingredients, etc. according to product design, in addition to proanthocyanidins and usability improvers.
  • auxiliary ingredients include ingredients that impart further functions to the dyslipidemia-improving agent and enhance the improvement of dyslipidemia. Examples include dietary fiber, soybean protein, carotenoids, and the like. can be done.
  • the above-mentioned antihypertensive agent can be used by blending it with functional foods, quasi-drugs, and pharmaceuticals.
  • the functional food in the present invention is a concept that includes general food that does not contain pharmaceutical ingredients and is said to contribute to the maintenance and promotion of health. It includes general foods such as so-called supplements, and foods with health claims such as foods for specified health uses, foods with nutrient claims, and foods with function claims.
  • quasi-drugs have a mild effect on the human body and are designated by the Minister of Health, Labor and Welfare. Examples include designated quasi-drugs sold at pharmacies or drug stores.
  • compositions are intended to be used for the diagnosis, treatment, or prevention of diseases. and OTC drugs that are available.
  • dyslipidemia-improving agent an effect equivalent to the dyslipidemia-improving action obtained by ingesting a predetermined number of proanthocyanidins can be expressed with a smaller number of times of ingestion, and storage stability and usability are improved. It is possible to provide a dyslipidemia improving agent that improves.
  • the description of each structure mentioned above is an example of this invention, and is not limited to these.
  • dyslipidemia improving agent according to the present embodiment will be further described with reference to actual production examples and results of effect confirmation tests.
  • test formulation [1] Verification test of dyslipidemia-improving agent (1-1) Preparation of dyslipidemia-improving agent They were mixed to obtain a test formulation (food).
  • the test formulation (food) was in the form of granules with a total amount of 1.5 g.
  • sample formulations test formulations containing usability enhancers are referred to as sample formulations.
  • a comparative formulation consisting of proanthocyanidins and excipients was also prepared.
  • the formulations of sample formulations and comparative formulations are as shown in Table 1 below. In the table, the origin or substance name of each component is shown in parentheses. For proanthocyanidins, the blending amount as an acacia bark extract is shown. Acacia bark extract contains more than 600 mg/g of proanthocyanidins.
  • Green tea leaves and roasted tea leaves in the table mainly indicate the amount of the free catechin source. Green tea leaves generally contain about 50 to 55 mg/g of free catechins, and hojicha leaves generally contain about 12 to 15 mg/g of free catechins.
  • each of the 10 panelists was trained in a preliminary test conducted prior to the test so that the degree of color tone evaluation by visual observation was roughly the same by referring to a predetermined color sample of the same color system.
  • the comparison tablet resulted in a larger color change than the sample formulation containing the usability improver.
  • the usability enhancer improved the stability of the sample preparation, in other words, improved the handling difficulty.
  • the blood LDL cholesterol level decreased the most when the sample formulation containing the usability improver was continuously ingested once a day (30 minutes before dinner).
  • the usability-improving agent provides an effect equivalent to or greater than that obtained when the comparative formulation is ingested three times a day (30 minutes before each meal), even with a small number of ingestions.
  • a non-sustainable improvement in amelioration of dyslipidemia was shown.
  • Oral irritation confirmation test (astringency sensory evaluation test)
  • the proanthocyanidins contained in the sample preparations are components with strong astringent and astringent tastes, and when added to foods, etc., it is known that the strongly irritating astringent and astringent tastes cause an unpleasant taste.
  • 10 men and women (ages 20 to 60) who have been engaged in product prototyping and sensory evaluation for many years at an OEM manufacturing facility for health foods were selected as panelists to evaluate the odor and taste. .
  • astringency since there are no objective evaluation methods, intensity units or scales, or standard substances, panelists were asked to rate the astringency on a 5-point scale (0 points: no astringency, 1 point: slightly astringent taste). 2 points: feel astringent but can drink without difficulty, 3 points: feel strong astringency and are difficult to drink, 4 points: feel extremely strong astringency and cannot drink.). The evaluation values were aggregated and the average value was obtained. Each panelist was allowed to appropriately ingest the preparation for comparison when confirmation of the standard of astringency was required.
  • the comparative tablet had a stronger astringent taste than the sample formulation containing the usability improver. That is, it was shown that the astringent taste of proanthocyanidins in the sample formulation was alleviated by the usability improver, and the ease of drinking of the formulation was improved.
  • the subjects were 10 subjects (5 males and 5 females) in a group (hereinafter referred to as a test group) ingesting the basic prescription A1 of the dyslipidemia improving agent according to this example, and a group in which the comparative sample X1 was ingested.
  • a test group a group in which the comparative sample X1 was ingested.
  • X1 group 10 people (5 men, 5 women), and 10 people (5 men, 5 women) in the group ingesting comparative sample X2 (hereinafter referred to as X2 group).
  • 10 people (5 males, 5 females) were randomly assigned to a group to receive sample X3 (hereinafter referred to as X3 group) from males and females satisfying the condition of a blood LDL cholesterol level of less than 140 mg/dL.
  • Groups X1 to X3 are also collectively referred to as a comparison group in the following description.
  • the test group showed a decrease in the blood LDL cholesterol level, but in the comparison group, the decrease in the blood LDL cholesterol level was about 1/4 to 1/3 of the test group.
  • the dyslipidemia-ameliorating agent containing both the free catechin and the cyclic oligosaccharide is more effective in improving the dyslipidemia.
  • the total amount of proanthocyanidins was the same as in the basic formula P1, but the P7 group, which was given a comparative sample P7 containing acacia-derived proanthocyanidins, cinnamon-derived proanthocyanidins, and hemp seed-derived proanthocyanidins, showed a It was shown that the blood LDL cholesterol level decreased more than the ⁇ P6 group. In other words, it was shown that the effect of improving dyslipidemia is enhanced by combining multiple proanthocyanidins of different origins.
  • D4-D6 groups ingested D6, and the total amount of free catechins is the same as samples D1 and D2, but sample D7 was selected from three sources of free catechins: green tea, roasted tea, and black tea. The D7 group was compared and examined. Sample D4 has the same formulation as basic formulation A1 in Table 2. The results are shown in FIG.
  • no reduction in blood LDL cholesterol levels was observed.
  • sample D6 in which two types of free catechin sources, hojicha leaves and black tea leaves, were selected showed a reduction in blood LDL cholesterol levels equivalent to that of the D4 group.
  • the D7 group which was given sample D7, which was selected from green tea leaves, hojicha leaves, and black tea leaves, as free catechin sources, the blood LDL cholesterol level was shown to decrease more than the D4 to D6 groups. was done.
  • the usability is improved in improving dyslipidemia, that is, dyslipidemia improving effect without increasing the amount of proanthocyanidin was shown to improve.
  • the dyslipidemia improving agent As described above, according to the dyslipidemia improving agent according to the present embodiment, it is composed of proanthocyanidins and a feel-improving agent, and free catechins and cyclic oligosaccharides are added as the feel-improving agent. , the dyslipidemia-improving agent effect can be expressed with a smaller amount of proanthocyanidin, and an easy-to-drink dyslipidemia-improving agent with reduced bitterness can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne un améliorant de la dyslipidémie qui présente une aptitude au stockage et une sensation en utilisation améliorées, et qui permet, en un nombre réduit de prises, de produire les mêmes effets que l'action d'amélioration de la dyslipidémie obtenue par la prise d'une proanthocyanidine un certain nombre de fois.　L'améliorant de la dyslipidémie est composé d'une proanthocyanidine et d'un exhausteur de sensation en utilisation, l'exhausteur de sensation en utilisation présentant une catéchine libre mélangée avec un oligosaccharide cyclique. L'invention concerne également des aliments fonctionnels, des quasi-médicaments et des médicaments qui contiennent cet améliorant de la dyslipidémie.
PCT/JP2022/046115 2021-12-14 2022-12-14 Améliorant de la dyslipidémie contenant de la proanthocyanidine, et aliments fonctionnels, quasi-médicaments et médicaments contenant un améliorant de la dyslipidémie contenant de la proanthocyanidine Ceased WO2023112973A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023553145A JP7537812B2 (ja) 2021-12-14 2022-12-14 プロアントシアニジンを含む脂質異常症改善剤並びに同脂質異常症改善剤を含む機能性食品、医薬部外品及び医薬品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021202736 2021-12-14
JP2021-202736 2021-12-14

Publications (1)

Publication Number Publication Date
WO2023112973A1 true WO2023112973A1 (fr) 2023-06-22

Family

ID=86774340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/046115 Ceased WO2023112973A1 (fr) 2021-12-14 2022-12-14 Améliorant de la dyslipidémie contenant de la proanthocyanidine, et aliments fonctionnels, quasi-médicaments et médicaments contenant un améliorant de la dyslipidémie contenant de la proanthocyanidine

Country Status (2)

Country Link
JP (1) JP7537812B2 (fr)
WO (1) WO2023112973A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH104919A (ja) * 1996-06-21 1998-01-13 Toyo Seito Kk 飲食物およびその製造方法
JP2006016367A (ja) * 2004-07-05 2006-01-19 Suntory Ltd リパーゼ阻害剤
WO2007125644A1 (fr) * 2006-04-26 2007-11-08 Ito En, Ltd. Inhibiteur d'absorption de graisses
JP2010503609A (ja) * 2006-05-05 2010-02-04 オムニカ ゲーエムベーハー キーウィ抽出物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022082A (ja) 2003-11-17 2006-01-26 Toyo Shinyaku:Kk 脂質代謝改善剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH104919A (ja) * 1996-06-21 1998-01-13 Toyo Seito Kk 飲食物およびその製造方法
JP2006016367A (ja) * 2004-07-05 2006-01-19 Suntory Ltd リパーゼ阻害剤
WO2007125644A1 (fr) * 2006-04-26 2007-11-08 Ito En, Ltd. Inhibiteur d'absorption de graisses
JP2010503609A (ja) * 2006-05-05 2010-02-04 オムニカ ゲーエムベーハー キーウィ抽出物

Also Published As

Publication number Publication date
JP7537812B2 (ja) 2024-08-21
JPWO2023112973A1 (fr) 2023-06-22

Similar Documents

Publication Publication Date Title
AU628514B2 (en) Inhibitive agent against activity of alpha-amylase
KR101412221B1 (ko) 구기자잎 추출 분말과 베타인을 유효성분으로 함유하는 항비만 조성물
US20120052138A1 (en) Composition comprising green tea extract
US20030161903A1 (en) Carbohydrate Aborption Inhibitor and Method for Manufacturing the Same
US20070275104A1 (en) Food Compositions and Methods of Treating Periodontal Disease
US20090175843A1 (en) Composition for prevention or treatment of urinary tract infection
CA2564326A1 (fr) Composition nutritionnelle permettant de perdre du poids, de bruler des calories, d'augmenter la thermogenese, de favoriser le metabolisme energetique et/ou de suprrimer l'appetit
US20240325348A1 (en) Kaempferol analog-containing composition
JP6335508B2 (ja) 成長ホルモン分泌促進剤
Vieira et al. A beverage containing ora-pro-nobis flour improves intestinal health, weight, and body composition: A double-blind randomized prospective study
WO2007019526A2 (fr) Compositions et procedes pour controler l'apport de glucose et de lipide par des aliments
JP2009173652A (ja) 紅茶エキスを有効成分とする中性脂肪吸収阻害用組成物
CN101254223A (zh) 石榴皮和石榴籽提取物改善前列腺症状的新用途
WO2004112510A1 (fr) Ameliorateur de physiologie de mouvement
WO2020175579A1 (fr) Composition contenant un extrait végétal et/ou un produit transformé d'origine végétale
WO2023112973A1 (fr) Améliorant de la dyslipidémie contenant de la proanthocyanidine, et aliments fonctionnels, quasi-médicaments et médicaments contenant un améliorant de la dyslipidémie contenant de la proanthocyanidine
US12194052B2 (en) Chlorophyll composition
KR20220110931A (ko) 황칠나무 추출물을 포함하는 치주질환 예방, 개선 또는 치료용 조성물
Airaodion et al. Chemical composition and nutraceutical potential of velvet tamarind (Dialium guineense Wild) fruit pulp
KR101142759B1 (ko) 염증성 장 질환 개선제 조성물
WO2010075611A1 (fr) Composition comprenant de la proanthocyanidine, une enzyme protéolytique et une substance de l'espèce aloe vera/agave
WO2005074961A1 (fr) Agent luttant contre les reserves lipidiques de l'organisme
JP2007051096A (ja) 口腔用組成物
JPWO2005082390A1 (ja) 脂肪蓄積抑制剤
US20180110792A1 (en) Compositions and methods for inhibiting glycation reactions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22907496

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023553145

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22907496

Country of ref document: EP

Kind code of ref document: A1